ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright

ALX Oncology (NASDAQ:ALXO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.67.

ALX Oncology Price Performance

NASDAQ:ALXO opened at $1.79 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm has a market cap of $94.41 million, a price-to-earnings ratio of -0.60 and a beta of 1.04. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The firm’s 50-day simple moving average is $1.49 and its 200 day simple moving average is $3.40.

Insider Buying and Selling

In other news, Director Rekha Hemrajani acquired 30,000 shares of the stock in a transaction on Monday, December 2nd. The stock was acquired at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 33.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ALX Oncology

Large investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new stake in shares of ALX Oncology during the 2nd quarter worth $1,834,000. GSA Capital Partners LLP acquired a new position in ALX Oncology during the third quarter worth about $88,000. Marshall Wace LLP lifted its holdings in shares of ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after acquiring an additional 6,888 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.